This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Malignant Glioma.

NCT00032903 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

59

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Glioma

Interventions

DRUG: Gimatecan® (ST 1481)

Sponsor

Sigma-Tau Research, Inc.

Collaborators

[object Object]